Related Experiment Videos
[Results of the ECHODIAH clinical trial on hip arthrosis]
1Service rhumatologie, Centre Hospitalier, Lyon Sud, 69495 Pierre Bénite.
Insights
Diacerein demonstrated a chondroprotective effect in hip osteoarthritis patients over three years. This osteoarthritis treatment significantly slowed joint space narrowing progression compared to placebo.
Area of Science:
- Rheumatology and Orthopedics
- Pharmacology
Background:
- Hip osteoarthritis is a degenerative joint disease causing pain and disability.
- Assessing chondroprotective agents is crucial for managing osteoarthritis progression.
Purpose of the Study:
- To evaluate the chondroprotective potential of diacerein versus placebo in hip osteoarthritis.
- To assess the effect of diacerein on joint space narrowing progression over three years.
Main Methods:
- The ECHODIAH study was a 3-year clinical trial.
- Joint space narrowing progression was the primary endpoint for assessing treatment efficacy.
Main Results:
- Diacerein significantly reduced the number of patients experiencing joint space narrowing aggravation.
- A 32% joint space narrowing sparing effect was observed in the diacerein group.
- Mean joint space narrowing progression decreased from 0.18 mm/year to 0.13 mm/year with diacerein treatment.
Conclusions:
- Diacerein exhibits a significant chondroprotective effect in hip osteoarthritis.
- Diacerein offers a potential therapeutic option for slowing osteoarthritis progression.
Study Objective:
The principal objective of ECHODIAH study conducted in patients with hip osteoarthritis was to evaluate the chondroprotective effect of potential of diacerein compared with placebo. The study was conducted over a 3-year period using progression of joint space narrowing as the assessment criterion.
Results:
For aggravation, expressed as joint space narrowing of at least 0.5 mm, there were significantly fewer patients in the diacerein group than in the placebo group; aggravation came significantly later in the diacerhein group. In the population of patients who completed at least 3 months treatment, the sparing effect on joint space narrowing was 32% in the diacerhein group compared with the placebo group. In addition, the mean progression of joint space narrowing was significantly less in patients treated with diacerein; the mean progression decreased from 0.18 mm/year at the end of the first year to 0.13 mm/year at the end of the third year.